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An Exploratory Study of Suboxone (Buprenorphine/ 
Naloxone) Film Splitting: Cutting Methods, Content 
Uniformity, and Stability
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Abstmct
Suboxone films are U.S. Food and Drug Administration approved to treat 
opioid dependence. White the package insert states that films should not be 
cut, physicians olten prescribe film fractions for treatment and tapering. There 
is no data to support this practice, and this study was initiated to evaluate 
cutting methods, content uniformity, and stability of split films. Suboxone 
8-mg buprenorphine/2-mg naloxone films were split using four methods: 1) 
ruler/razor cut, 2) scissor cut, 3) fold/rip, and 4) fold/scissor cut. United States 
^mmacopela Chapter <905> was used to evaluate the weight variation and 
content uniformity of split films. The stability of split films stored in polybags 
was evaluated over 7 days. A stability-indicating high-performance liquid 
chromatography method was used for content uniformity and stability 
evaluation. The weight variation results were acceptable for the half films from 
all four cutting methods, but this was not true for the quarter films. The method 
of ruler/razor cut was determined most favorable and used for the content 
uniformity test. Based on the high-performance liquid chromatography results, 
tbe half films from the ruler/razor cut method met the passing criteria of United 
States Pharmacopeia Chapter <905> with acceptance values of 9.8 to 10.4 for 
buprenorphine and 8.4 to 11.5 for naloxone (^15 Is considered passing). The 
stability results indicated that both actives retained >97.7% of initial strength. 
Fmir cutting methods were found to be acceptable for splitting Suboxone films 
into half but not quarter fractions. The half films from the ruler/razor cut 
method also passed United States Pharmacopeia Chapter <905> content 
uniformity test. Both actives remained stable for 7 days when the half films 
were stored in potybags at room temperature.
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Introduction
In 2016, an estimated 2.1 million individ­
uals were reported to have substance-use 
disorder related to opioid pain medica­
tions.^ Currently, there are three treatment 
options for opioid use disorder: 1) metha­
done, 2) buprenorphine (with or without 
naloxone), and 3) naltrexone.^ Among these, 
buprenorphine represents a preferred treat­
ment option due to its unique mechanism of 
action as a partial agonist at the mu opioid 
receptor with high affinity and slow dis-
The authors are affiliated with St. John 
Fisher College, Rochester, New York.
sociation.® This partial agonist property 
increases the safety profile of buprenor­
phine because the ceiling effect limits the 
potential life-threatening side effects asso­
ciated with overdose.
The combination of buprenorphine with 
naloxone is used as an abuse deterrent 
strategy.^’® Naloxone is an opioid antagonist, 
and it has a relatively low bioavailability via 
the oral, sublingual, or buccal routes. When
the buprenorphine/naloxone dosage forms 
are used as directed, naloxone has little to 
no effect. If a patient tries to adulterate the 
product for intravenous administration, the 
naloxone would become bioavailable and 
precipitate withdrawal. Patients initiated 
on buprenorphine/naloxone therapy may 
stay on therapy indefinitely; however, taper­
ing a patient off therapy is common in clini­
cal practice. Both American and Canadian
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guidelines state that discontinuation of buprenorphine products 
may be a slow and prolonged process, possibly months to years.®'^ 
However, neither the guidelines nor the product labeling provide 
any recommendations on the tapering dose or schedule.
Among the buprenorphine/naloxone dosage forms, the Suboxone 
sublingual films are frequently prescribed for opioid dependence 
treatment emd tapering. Despite clear product labeling that films 
should not be cut or torn,® personal communications with commu­
nity pharmacies indicate that patients are often prescribed to use 
partial films such as I'/z or 114 films. Internet community discus­
sion boards and pharmacy benefits management services have also 
discussed cutting the films £is a means to save cost and/or allow for 
dose titration.®'^® Some websites focus on cutting the films to assist 
with dose tapering, with recommendations for cutting the film into 
as small as 1/16 of the original size.^° A literature search did not find 
any reliable published data to support such practices.
Current data does not indicate if the active ingredients in the 
film are uniformly distributed across the entire film, making the 
reliability of dose accuracy in split films unclear. Suboxone films 
do not contain any scoring or perforation to allow for accurate split­
ting, increasing the potential for dose variability among split-film 
fractions. Another potential source of dose variation is the stabil­
ity of the split films. Suboxone films are packaged individually in 
polyester/foil laminated pouches intended for single use.® Once 
opened, it is uncertain if the active ingredients remain stable over 
time. As shown in FIGURE 1, the chemical structures of buprenorphine 
and naloxone® contain several functional groups which are prone to 
hydrolysis and oxidation.
The lack of data supporting the practice of film splitting lends 
itself for study. The purpose of this study is to evaluate the accuracy 
of common methods used to cut Suboxone films and to assess the 
cut fractions for content uniformity as well as stability outside the 
original packaging.
Methods
MATERIALS
Multiple lots of Suboxone (8 mg buprenorphine and 2 mg naloxone) 
sublingual films, manufactured by Indivior Inc. (NDC12496-1208-1; 
Richmond, Virginia), were purchased between 2016 tuid 2018. For 
the high-perform£uice liquid chromatography (HPLC) method, aU 
solvents were purchased from Fisher Scientific (Fair Lawn, New 
Jersey); polytetrafluoroethylene (PTFE) syringe filters, 0.45-|xm 
pore size, and 15-mm diruneter, were purchased from Phenomenex 
(Torrance, California). For the stability study of split-film fractions,
3" X 5" and 2-mil low-density polyethylene bags (polybags) were pur­
chased from Total Pharmacy Supply (Arlington, Texas).
FILM SPLITTING
Four splitting methods were evaluated in this study: 1) ruler/razor 
cut, 2) scissor cut, 3) fold/rip, and 4) fold/scissor cut. The specific 
details ofeach method are described in TRBIE1 and shovm in FIGURE 2.
www.IJPC.com
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A total of 18 whole films (from three different lots) were used for 
each splitting method. Individuals completing the film splitting 
were provided with the written instructions shown in TA BIE1. All 
methods were performed on a clean, glass ointment slab while 
wearing gloves. Each film was cut midway of the long sides of the 
film into halves or quarters.
WEIGHT VARIATION OF SPLIT FILMS
The weight variation approach from United States Pharmacopeia 
(USP) Chapter <905> was used with modification to evaluate and
FIGURE 1.
CHEMICAL STRUCTURES OF (A) BUPRENORPHINE 
HYDROCHLORIDE AND (B) NALOXONE HYDROCHLORIDE.®
A B
TABIE1.
FILM-SPLITTING METHODS AND INSTRUCTIONS.
SPLITTING
METHOD
Ruler/F!azor Cut
Scissor Cut
Fold/Rip
Fold/Scissor Cut
INSTRUCTIONS
Use the ruler to measure the longer sides of the film. 
Mark the halfway points by scoring the film with the 
razor.
Line up the ruler across both marks scored in the film. 
Use the razor to cut the film in half by connecting both 
halfway points while applying pressure to the ruler to 
ensure the film does not move.
1. Visually estimate the halfway points of the longer sides 
of the film without using any measuring devices.
2. Use the scissors to cut the film across the estimated 
halfway points.
1 Fold the film in half and apply pressure to form a crease.
2. Unfold the film.
3. Pinch both halves of the film on opposite sides of the 
crease.
4. Tear the film by pulling one side towards your body and 
the other side away, rather than pulling both pieces to 
the side.
1 Fold the film in half and apply pressure to form a crease.
2. Unfold the film.
3. Use the scissors to cut the film along the crease.
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compare the accuracy and variability of 
the four splitting methods.^^ Each whole 
film was weighed prior to splitting, and this 
value was used to calculate the expected 
weight of the half and quarter films. After 
splitting, the half or quarter portions were 
immediately weighed. The weight of each 
split film was divided by the expected value 
and expressed as the percent expected 
weight. The standard deviation (SD) was 
calculated for each splitting method, and 
an SD of <6% was considered acceptable.^^ 
For direct comparison across the splitting 
methods, the absolute value of the weigh 
difference (observed weight - expected 
weight) was also calculated for each split 
film and used for student t-test analysis. 
Statistical significance was established if P 
was <0.05. As a control for potential mois­
ture uptake/loss, a set of three films were 
removed from the foil packets and exposed 
to the same laboratory atmosphere for the 
typical duration of the experiments; no sig­
nificant change in weight was observed.
DRUG CONTENT UNIFORMITY OF 
SPLIT FILMS
Based on the weight variation results, 
splitting the films into halves was accept­
able, and ruler/razor cut was the method of 
choice. The content uniformity test of USP 
Chapter <905>^^ was then carried out using 
an HPLC method to quantitate the amount of 
the two active ingredients in the split films. 
Ten whole and ten half films were evalu­
ated as per USP requirement. The ten half 
films were obtained by splitting five whole 
films using the ruler/razor cut method. Each 
whole or half film was dissolved in a suf­
ficient amount of water to yield a theoretical 
concentration of 80 Bg/mL buprenorphine 
and 20 fig/mL naloxone. About 1-mL aliquot 
from each sample was filtered through a 
PTFE syringe filter and collected in a vial 
for the HPLC assay. The content uniformity 
test was conducted on three separate lots 
of the films with each lot being evaluated 
on a different day. The percent label claim 
was calculated for each lot, and the mean 
and standard deviation values were used 
to calculate the acceptance value (AV) as
described in USP <905>.’^^ An AV of <15 was 
considered passing.
STABILITY OF SPLIT FILMS
A 7-day stability study was conducted to 
evaluate the physical and chemical stabil­
ity of the split films outside the original 
polyester/foil pouch. Films were removed 
from packaging and split in half. Each half 
film was placed into a polybag and stored 
at room temperature. On Day 0,1,3, and 
7, three replicate samples were pulled for 
analysis by visual inspection and HPLC. 
Each half film was dissolved in a sufficient 
amount of water to yield a theoretical con­
centration of 80 |lg/mL buprenorphine 
and 20 Bg/mL naloxone. Standards were 
included for the HPLC assay on each day for 
calibration purpose. Samples were consid­
ered stable if there was less than 10% loss of 
each active.
HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY ASSAY
A stability-indicating HPLC method was 
developed to assay the content of buprenor­
phine and naloxone in the films and to 
monitor their stability when stored outside 
the original packaging. The analysis was 
performed using a Shimadzu LC-2010AHT 
system (Shimadzu Scientific Instruments, 
Marlborough, Massachusetts) with a 
Phenomenex C18 column (Kinetex, 150 x 
4.6 mm, 5 Bm, 100 A). The mobile phase 
consisted of two channels: A = water with 
0.1% v/v TFA and B = acetonitrile with 
0.1% v/v TFA. Due to the vastly different 
polarity of the two actives, a linear gradi­
ent was used from 15% to 55% of B over 10 
minutes with a 5-minute re-equilibration 
period. The column oven temperature 
was maintained at 40°C, and the flow rate 
was 0.8 mL/min. All samples were passed 
through the PTFE 45-Bm syringe filters 
prior to analysis, and the injection volume 
of each sample was 50 bL. The UV detection 
wavelength was set at 280 nm. Under these 
conditions the retention time for naloxone 
was around 4.0 minutes and buprenorphine 
around 9.8 minutes. A representative chro­
matogram is shown in FIEIRE 3.
International Journal of Pharmaceutical Compounding
260 Vol. 23 No. 3 I May: June : 2019
FI61IRI 2.
VISUAL REPRESENTATION OF THE 
FOUR FILM-CUTTING METHODS.
A. Ruler/Razer Cut
D. Fold/Scissor Cut
Standard solutions of naloxone and 
buprenorphine were prepared for calibra­
tion purpose. Due to the regulatory barri­
ers to obtain pure buprenorphine powder, 
calibration standards were prepared using 
Suboxone films (one from each correspond­
ing lot) with the assumption that they 
contain 100% of the label claim quantity of 
each active. The concentrations of the stan­
dard solutions ranged from 64/16 BS/mL 
to 96/24 BS/mL buprenorphine/naloxone, 
covering 80% to 120% of the theoretical 
concentration of study samples. A calibra­
tion curve was constructed on each analysis 
day by linear regression of the peak area and 
drug concentration; separate curves were 
made for buprenorphine and naloxone. All 
calibration curves had a value of 0.99 or
better, confirming linearity over the con­
centration range of interest.
A forced degradation study was con­
ducted to verify the ability of the above 
gradient HPLC method to separate the
www.IJPC.com
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potential degradation products from the two active ingredients. An 
80/20 |tg/mL buprenorphine/naloxone solution was prepared by 
dissolving a Suboxone film in water. The solution was divided into 4 
different samples.
• Sample #1 was adjusted to a pH of 2 with IM hydrogen chloride and 
incubated in a 60°C oven.
• Sample #2 was adjusted to a pH of 12 with IM sodium hydroxide and 
incubated in a 60°C oven.
• Sample #3 was spiked with 3% (final concentration) hydrogen 
peroxide and incubated in a 60°C oven.
• Sample #4 was spiked with 3% (final concentration) hydrogen peroxide 
and was stored at room temperature and exposed to direct sunlight.
After 48 hours, complete degradation of both actives was 
observed in Sample #3 (peroxide/60°C). A significant amount of 
degradation (32% to 65%) was also observed for Sample #2 (pH 
12/60°C) and Sample #4 (peroxide/light). Both actives remained 
stable in Sample #1 (pH 2/60°C). All the degradation products were 
separated from the two active ingredients, and no interfering peaks 
were observed. The gradient HPLC method was considered to be 
stability indicating and suitable for the content uniformity and sta­
bility evaluation.
Results and Discussion
While multiple sources suggested that patients are splitting 
Suboxone sublingual films, no data are available to support this 
practice. Several studies conducted on traditional tablets provided 
context and discussed challenges associated with splitting dos­
age forms.^^'^'* Sublingual films are a relatively new class of dosage 
forms with unique properties. To the authors’ knowledge, this is the 
first study to evaluate film-splitting methods and content unifor­
mity of the resulting film fractions.
EVALUATION OF FILM-SPLITTING METHODS
All four splitting methods were carried out successfully without 
major handling issues. However, several limitations were observed. 
Due to the small size of the film, all methods required manual dex­
terity and visual acuity. The films also did not tear easily along a 
fold, so it was important to follow the exact directions included in 
Table 1 for the fold/rip method. Cutting accurately along the fold 
using scissors was also found to be more difficult than expected.
The weight variation results of the split films are summarized in 
TABLE 2. For the half films, the standard deviation of the four splitting 
methods ranged from 3.4% to 4.8%, which met the passing crite­
ria of 6%. However, for the quarter films, the standard deviation 
increased for each splitting method, and only the ruler/razor cut 
method passed the test with a value of 5.2%. Similar trends were 
observed from the student t-test analysis of the absolute weight dif­
ferences (actual - expected) among the four splitting methods as 
shown in TABLE 3. For half films, using scissors to split the films led
FIGURE 3.
A REPRESENTATIVE CHROMATOGRAM OF BUPRENORPHINE 
AND NALOXONE USING THE HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY METHOD DEVELOPED FOR THE 
CONTENT UNIFORMITY AND STABILITY EVALUATION.
Buprenorphine
1 Naloxone
0.0 2.5 5.0 7.5 10.0 12.5 15.0
Minutes
IftBLE 2.
WEIGHT VARIATION RESULTS OF THE SPLIT FILMS FOR THE 
FOUR SPLITTING METHODS.
SPLITTING
METHOD
% EXPECTED WEIGHT, MEAN ± SD
HALF FILMS QUARTER FILMS
(«=36) {»=72)
Ruler/Razor Cut 98.9 ± 3.4 99.2 + 5.2
Scissor Cut 99.1 ± 4.6 98.8 ± 6.8
Fold/Rip 98.9 + 4.5 97.2 ± 7.3
Fold/Scissor Cut 98.4 ± 4.8 97.3 ± 7.1
to a significantly greater weight difference compared to the other 
three splitting methods combined (ruler/razor, fold/rip, fold/scis­
sor); 0.85 vs. 0.60, P=0.032. The quarter films indicated a similar 
trend with the two scissor methods yielding greater weight differ­
ences; however, only the results of the fold/scissor method were 
statistically significant (0.60 vs. 0.50, P=0.013). Additionally for 
the quarter films, the fold/rip method had a significantly smaller 
weight difference compared to the other three methods (0.48 vs. 
0.55, P=0.025); this might be due to the fact that the other three 
methods included the two scissor methods.
Based on the overall weight results, splitting the Suboxone 
(8 mg buprenorphine/2 mg naloxone) films into halves was 
considered acceptable using all four cutting methods, with the 
scissor cut method being the least consistent. However, splitting 
the films into quarters or beyond was not acceptable due to sig­
nificant weight variation.
www.IJPC.com International Journal of Pharmaceutical Compounding
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TABLE 3.
COMPARISON OF THE FOUR SPLITTING METHODS USING THE ABSOLUTE WEIGHT DIFFERENCE OF THE SPLIT FILMS.
SPLITTING HALF FILMS QUARTER FILMS
METHODS MEAN (SD) MEDIAN (IQR) P-VALUE MEAN (SD) MEDIAN (IQR) F-VALUE
Ruler/Razor Cut
Other 3 Methods
0.69 (0.49)
0.84 (0.76)
0.60 (0.35 to 0.90) 
0.65 (0.35 to 1.10)
0.567 0.54 (0.40)
0.67 (0.58)
0.44 (0.23 to 0.69) 
0.55 (0.25 to 0.94)
0.184
Scissor Cut
Other 3 Methods
0.93 (0.59)
076 (0.73)
0.85 (0.48 to 1.40) 
0.60 (0.30 to 0.95)
0.032 0.67 (0.47)
0.63 (0.56)
0.55 (0.28 to 1.00) 
0.50 (0.23 to 0.85)
0.285
Fold/Rip
Other 3 Methods
0.73 (0.82)
0.83 (0.66)
0.50 (0.25 to 0.85) 
0.75 (0.40 to 1.10)
0.075 0.58 (0.65)
0.66 (0.50)
0.48 (0.16 to 0.78) 
0.55 (0.28 to 0.94)
0.025 1
Fold/Scissor Cut
Other 3 Methods
0.86 (0.84)
0.78 (0.65)
0.68 (0.30 to 1.00) 
0.65 (0.35 to 1.00)
0.837 0.77 (0.58)
0.60 (0.52)
0.60 (0.38 to 1.10) 
0.50 (0.23 to 0.82)
0.013
Absolute weight difference (mg) = | actual weight (mg) - expected weight (mg) 1. IQR = interquartile range; SD = standard deviation. 
Note: The bolded results represent a statistically significant difference for the splitting method when compared to the other methods.
CONTENT UNIFORMITY OF SPLIT FILMS
While the weight variation results provided useful informa­
tion, direct measurement of the active ingredients by HPLC was 
necessary to confirm the actual drug contents in the split films.
To this end, the content uniformity test procedure of USP <905> 
was applied to analyze the half films prepared by the ruler/razor 
cut method.^^ Three different lots were tested in case there was 
any significant lot-to-lot variability. The whole films were also 
analyzed for comparison purpose. The content uniformity Euialy- 
sis was performed for both buprenorphine and naloxone, and the 
acceptance value (AV) was calculated using the formula in USP 
<905>. As shown in TABLE 4, the AV results of buprenorphine ranged 
from 7.2 to 12.1 for the whole films and 9.8 to 10.4 for the half films. 
Similarly in Table 5, the AV results of naloxone ranged from 8.2 to 
11.1 for the whole films and 8.4 to 11.5 for the half films. According 
to USP <905>, an AV of < 15 is considered passing.^^ Based on this 
criterion, the content uniformity of buprenorphine and naloxone 
was considered acceptable in the half films from all three lots. 
Additionally, the AV values of the half films were comparable to 
those of the whole films.
STABILITY OF SPLIT FILMS
Based on the chemical structures (Figure 1) and the forced stabil­
ity study results (Methods section), there was a potential concern 
for the stability of buprenorphine and naloxone once the films are 
removed from the original packaging. The physical stability of the 
films was also unknown. A 7-day stability study of the split films 
was conducted to address these concerns. The half films were 
stored in polybags at room temperature. Based on visual inspec­
tion, the films appeared to lose some flexibility over seven days, but 
they did not become too fragile for normal handling. The chemical 
stability was monitored by the stability-indicating HPLC assay, and 
the results are shown in TABLE 6. Both buprenorphine and naloxone 
retained >97.7% of their initial strengths over the study period.
TABLE A.
CONTENT UNIFORMITY RESULTS OF BUPRENORPHINE IN 
WHOLE AND SPLIT FILMS.
SAMPLE NUMBER
OF UNITS
BUPRENORPHINE
CONTENT
(% LABEL CLAIM),
MEAN ± SD
AV
Whole film, Lot 1 10 105 ± 1.43 7.2
Whole film, Lot 2 10 107 ± 2,73 12.1
Whole film. Lot 3 10 109 ± 1.40 10.9
Half film, Lot 1 10 106 ± 2.44 10.4
Half film. Lot 2 10 105 ± 2.85 10.3
Halt film. Lot 3 10 106 ± 2,21 9.8
The acceptance value (AV) is calculated according to United States Pharmacopeia Chapter <905>, 
and the passing criteria is AV ^5.
TABLE 5.
CONTENT UNIFORMITY RESULTS OF NALOXONE IN WHOLE 
AND HALF FILMS.
NALOXONE
SAMPLE NUMBER
OF UNITS
CONTENT 
(% LABEL CLAIM),
AV
MEAN ± SD
Whole film. Lot 1 10 106 ± 1.61 8.2
Whole film. Lot 2 10 107 ± 2,09 10.5
Whole film. Lot 3 10 109 ± 1.50 11.1
Half film. Lot 1 10 107 ± 2.14 10.2
Half film. Lot 2 10 108 ± 2.09 11.5
Half film. Lot 3 10 108 ± 0.78 8.4
The acceptance value (AV) is calculated according to United States Pharmacopeia Chapter <905>, 
and the passing criteria is AV ^5.
SD • standard deviation
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TABLE 6.
CHEMICAL STABILITY OF THE TWO ACTIVE INGREDIENTS 
IN THE HALF FILMS STORED IN POLYBAGS OVER 7 DAYS 
AT ROOM TEMPERATURE (n=3 FOR EACH TIME POINT).
ACTIVE
INGREDIENT
INITiAI. DRUG
CONTENT CMG)^
% INITIAL DRUG CONTENT
REMAINING^ MEAN ± SD
MEAN ± SD DAY I DAY 3 DAY T
Buprenorphine 4.28 + 0.09 100.8 ± 0.8 99.5 ± 2.6 100.5 ± 3.6
Naloxone 108 ± 0.01 99.6 ± 1.3 97.7 ± 3.4 99.0 ± 2.8
SD = standard deviation
STUDY LIMITATIONS
First, this study only evaluated one strength (8 mg buprenor- 
phine and 2 mg naloxone) of Suboxone films. It is unknown if these 
findings also apply to the other strengths, since the package insert 
states that there is some variation in film composition between 
strengths.^ Secondly, due to regulatory challenges to obtain the 
pure buprenorphine powder, this study used a single Suboxone 
film to prepare the HPLC calibration standards on each analysis 
day. This may explain why the average drug content was >100% of 
the label claim in all samples (TABLES A AND 5). Nevertheless, this was 
taken into account for the calculation of the acceptance values, and 
the overall conclusions remained the same. In future studies, stan­
dards should be prepared using pure drug if attainable or a pooled 
solution of multiple films to improve accuracy of the standards.
Conclusion
Four cutting methods were found to be acceptable to split the 
Suboxone film (8 mg/2 mg strength) into half fractions based on 
weight variation data. Additionally, the content uniformity of 
the actives in the half films was confirmed for the ruler/razor cut 
method. The half films were stable for at least seven days when 
stored in polybags at room temperature. The data did not support 
cutting the films into pieces smaller than halves due to consider­
able weight variation between pieces.
It should be emphasized that this is an exploratory feasibility 
study. According to the package insert, the size and excipient com­
position of Suboxone films differ between the strengths, which in 
turn may affect the rate and extent of buprenorphine absorption.® 
Prescribing film fractions represents an off-label use, and patients 
should be closely monitored for symptoms related to over- or 
under-dosing. Due to the lack of available data to support the use of 
Suboxone film fractions to treat or taper opioid dependence, this 
practice should be approached carefully, and more clinical stud­
ies are needed. A call for scientific publication of relevant clinical 
practice is highly recommended.
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